BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

CN Group Announces Medical Carbon Research Institute To Present At Upcoming 2003 Bio Venture Capital Conference


10/19/2005 5:09:27 PM

AUSTIN, Texas, Dec. 5 /PRNewswire/ -- CN Group and the Texas Healthcare and Bioscience Institute announces that Medical Carbon Research Institute, LLC (MCRI(R)) has been selected as a presenting company at the 2003 Southwest Bio Venture Capital Conference. MCRI is an integrated biomaterials and cardiovascular therapeutic device company and the world leader in pyrolytic carbon technology, specializing in the development of cardiovascular and orthopedic device implant applications using its proprietary isotropic pyrolytic On-X(R) carbon technology. The company will present an overview of its technology and business strategy at the conference, to be held at the Hyatt Hotel in Houston on December 9th & 10th.

MCRI's premiere product is the FDA approved On-X(R) Prosthetic Heart Valve ("On-X valve"). The On-X valve represents a breakthrough in materials and design that has produced markedly improved results compared to other currently available prosthetic valves. MCRI recently announced the initiation of a clinical study of the On-X valve under an aspirin-only anticoagulation protocol. The aspirin-only protocol was approved by the German Ethics Commission based in Freiburg and by the individual participating German hospitals' local Ethics Committees. This is the first aspirin-only study on mechanical heart valves approved by any regulatory agency.

Additional applications of On-X carbon include its use as a coating for implantable therapeutic devices by third party companies. MCRI currently supplies coating and contract manufacturing services for orthopedic devices, including spinal and knee implants, to subsidiaries of two of the world's five largest orthopedic implant companies. MCRI also supplies contract manufacturing and coating services on finger joints to another orthopedic company for the treatment of various forms of arthritis.

"We are extremely excited to include MCRI in this year's conference," stated David Gerhardt, managing director, CN Events. "We are bringing together very advanced staged life sciences companies which speaks to the depth and diversity of the sector here in Texas."

About MCRI

Medical Carbon Research Institute ("MCRI") MCRI is the world leader in pyrolytic carbon technology specializing in the development of cardiovascular and orthopedic device implants using its proprietary isotropic pyrolytic On-X(R) carbon technology to significantly improve the quality of life of patients. Jack Bokros, Ph.D., and his associates founded MCRI in 1994 to further advance prosthetic heart valve technology by capitalizing on their new form of pyrolytic carbon. The Company gained FDA approval for the On-X(R) aortic valve in 2001 and approval on the On-X mitral valve in 2002. MCRI also provides carbon coating and contract manufacturing services to manufacturers of other medical products including orthopedic joint and spine implant devices. MCRI is headquartered in Austin, Texas, and maintains a wholly owned subsidiary, MCRI Deutschland GmbH, in Hannover, Germany. More information can be found at http://www.mcritx.com/ .

Media Contact: Clyde Baker 512-339-8000 x269 cbaker@mcritx.com About CN Group

CN Group helps build growth companies through three business efforts. CN Events produces the leading Venture Capital, Private Equity and Angel Investor gatherings in the Southwest. CN Management Services assists companies in building their management team and Board and Advisory Boards. Capital Network Securities, a NASD-approved investment bank, provides merger and acquisition advisory services, and capital-raising services for select growth companies. For more information please visit http://www.cngroupllc.com/ .

About Texas Healthcare and Bioscience Institute

Texas Healthcare and Bioscience Institute (THBI) is a public policy research organization whose members consist of biotechnology, medical device, and pharmaceutical companies; academic and private research institutions; chambers of commerce; and local and regional economic development foundations. The mission of THBI is to research, develop and advocate policies that promote life science innovation in Texas. For more information, visit http://www.thbi.com/ .

Media Contact: Patti D. Hill BlabberMouth Public Relations (512) 528 - 0201 patti@blabbermouthPR.com

CN Group; Texas Healthcare and Bioscience Institute

CONTACT: Patti D. Hill of BlabberMouth Public Relations,+1-512-528-0201, or patti@blabbermouthPR.com , for CN Group; or Clyde Baker ofMedical Carbon Research Institute, LLC, +1-512-339-8000 x269, orcbaker@mcritx.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES